Press release
Graves' Disease Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration by DelveInsight
Graves' Disease Clinical Trials
DelveInsight's "Graves' Disease Pipeline Insight, 2025" , report delivers a comprehensive analysis of the evolving therapeutic landscape for Graves' Disease (GD). With more than 10+ emerging treatment candidates in clinical and preclinical development, and 8+ leading pharmaceutical and biotech companies working on innovative therapies, the Graves' Disease market is witnessing significant transformation.
The report provides in-depth insights into clinical trials, drug mechanisms of action, routes of administration, product types, and ongoing research collaborations, making it an essential resource for stakeholders, investors, and healthcare professionals.
Unlock detailed insights into the Graves' Disease therapeutics by downloading the comprehensive report from DelveInsight @ [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Graves' Disease Market Report
* As per DelveInsight's estimates, Graves' disease is the primary cause of hyperthyroidism, responsible for 60-80% of cases. Despite this prevalence, it is relatively uncommon, impacting roughly 1.2% of the US population.
* According to American Thyroid Association (2024), more than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. Women are five to eight times more likely than men to have thyroid problems.
* As per data from the National Institute of Diabetes and Digestive and Kidney Diseases (2021), Graves' disease affects nearly 1 in 100 Americans.
* According to Shang et al. (2024), an estimated 2.7-3.0% of the adult Chinese population-over 31 million individuals-are affected by one or more autoimmune diseases, a prevalence comparable to that seen in Western populations. The predominant contributors to this burden are autoimmune thyroid diseases and rheumatoid arthritis.
* The leading Graves' Disease Companies such as Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
* Promising Graves' Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
Recent Developments in Graves' Disease Pipeline
The past year has witnessed several groundbreaking advancements in the Graves' Disease and TED pipeline:
* May 2025 - Amgen announced that the UK MHRA approved TEPEZZA Registered (teprotumumab) for moderate-to-severe TED, making it the first authorized treatment in the UK for adult TED patients.
* May 2025 - Viridian Therapeutics received FDA Breakthrough Therapy Designation for veligrotug (veli), an anti-IGF-1R candidate for TED.
* January 2025 - Sling Therapeutics reported topline efficacy and safety results from its Phase 2b/3 LIDS trial of linsitinib, an oral IGF-1R inhibitor for TED.
* December 2024 - Viridian Therapeutics shared positive Phase 3 results from its THRIVE-2 trial of veligrotug in chronic TED patients.
These developments highlight the growing focus on thyroid-associated ophthalmopathy and underline the expanding pipeline beyond traditional Graves' Disease therapies.
Gain a competitive edge in the Graves' Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Graves' Disease Competitive Landscape
Globally, several pharmaceutical and biotech companies are working relentlessly to address the gaps in treatment. According to DelveInsight's analysis, key companies in the Graves' Disease pipeline include:
* TSHR Septerna
* Cyclopeptides advanceCOR
* EVOQ Therapeutics
* Worg Pharmaceuticals
* AV7 Limited
* Novartis Pharmaceuticals
* Immunovant Sciences GmbH
* And others
These companies are developing therapies that target TSH receptor modulation, IGF-1R inhibition, monoclonal antibodies, and novel small molecules.
Emerging Therapies in the Graves' Disease Pipeline
The pipeline consists of therapies in different stages of development ranging from pre-clinical to late clinical phases. Some of the promising candidates include:
* Research Program (TSHR Septerna) - early-stage research focused on TSH receptor modulation.
* Cyclopeptides (advanceCOR) - peptide-based therapies with unique mechanisms.
* EVOQ Therapeutics Research Program - nanotechnology-driven approaches.
* WP-1302 (Worg Pharmaceuticals) - advancing in early clinical trials.
* K1-70 (AV7 Limited) - a monoclonal antibody targeting TSH receptor.
* CFZ533 (Novartis Pharmaceuticals) - a promising immunomodulatory therapy.
* Batoclimab (Immunovant Sciences GmbH) - a next-generation FcRn inhibitor with potential in autoimmune thyroid disorders.
These therapies are expected to reshape the Graves' Disease treatment landscape in the coming years, particularly for patients who do not respond to standard care.
Download DelveInsight's Graves' Disease Market report today and stay ahead in this rapidly evolving field. @ [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Graves' Disease Overview
Graves' Disease is the most common cause of hyperthyroidism, affecting millions worldwide. It is an autoimmune disorder in which the immune system attacks the thyroid gland, leading to the overproduction of thyroid hormones. Symptoms include unexplained weight loss, rapid heartbeat, anxiety, tremors, goiter (enlarged thyroid), and bulging eyes (Graves' ophthalmopathy or thyroid eye disease, TED).
Diagnosis is typically confirmed through blood tests measuring thyroid hormone levels, thyroid-stimulating immunoglobulins (TSIs), and imaging scans such as radioactive iodine uptake.
Traditional treatment options include antithyroid medications (methimazole, propylthiouracil), radioactive iodine therapy, and thyroidectomy (surgery). However, limitations such as relapse, side effects, and long-term complications have created unmet needs, fueling the search for novel biologics, monoclonal antibodies, and targeted therapies.
Graves' Disease Pipeline by Route of Administration (RoA)
Emerging products are being developed in multiple formulations for improved efficacy, safety, and patient convenience:
* Oral
* Parenteral
* Intravenous (IV)
* Subcutaneous (SC)
* Topical
Graves' Disease Molecule Types
Therapies under development also span a diverse range of molecule classes:
* Monoclonal Antibodies
* Peptides
* Polymers
* Small Molecules
* Gene Therapies
This diversity reflects the industry's multifaceted approach to targeting different pathways involved in Graves' Disease.
Discover key developments and opportunities in the Graves' Disease Market. Click here to learn more from DelveInsight's latest report @ [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Graves' Disease Market Dynamics - Drivers and Barriers
Key Graves' Disease Market Drivers
* Rising prevalence of Graves' Disease worldwide
* Growing awareness of early diagnosis and treatment
* Increased R&D investments by pharma and biotech companies
* Breakthrough drug designations and accelerated approvals
Key Graves' Disease Market Barriers
* High cost of biologic and antibody therapies
* Complications associated with traditional therapies
* Limited availability of targeted treatments in developing regions
Scope of the Graves' Disease Market Report
* Coverage- 7MM
* Graves' Disease Companies- Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals (SWX: NOVN), AV7 Limited, Medtronic (NYSE: MDT), Pfizer (NYSE: PFE), Sanguine Biosciences, Tourmaline Bio Inc. (NASDAQ: TRML), Horizon Pharma USA Inc., Viridian Therapeutics Inc. (NASDAQ: VRDN), Innovent Biologics Co. Ltd (HKEX: 1801), Hoffmann-La Roche (SWX: RO), and others.
* Graves' Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
* Graves' Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Graves' Disease Unmet Needs, KOL's views, Analyst's views, Graves' Disease Market Access and Reimbursement
Download the report to understand which factors are driving Graves' Disease Market Dynamics @ Graves' Disease Market Trends [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graves-disease-clinical-trials-outlook-2025-competitive-landscape-regulatory-milestones-therapies-in-development-mechanisms-of-action-and-routes-of-administration-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graves' Disease Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration by DelveInsight here
News-ID: 4194886 • Views: …
More Releases from ABNewswire
Chronic Rhinosinusitis with Nasal Polyps Clinical Trials Assessment 2025: Compet …
Chronic Rhinosinusitis with Nasal Polyps companies include Keymed Biosciences, Connect Biopharma, AstraZeneca, Amgen, Pfizer, Trellis Bioscience LLC, GlaxoSmithKline, Gossamer BioInc., Biohaven Pharmaceuticals, Inc., Insmed Incorporated, Lyra Therapeutics, And Many Others
According to DelveInsight's analysis, over 10 major pharmaceutical and biotech companies are developing more than 10 pipeline candidates for the Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) treatment landscape, encompassing various routes of administration, mechanisms of action, and molecule types. Several of…
Stargardt Disease Market Outlook 2034 - Clinical Trials, Market Size, Medication …
Stargardt Disease Companies in treatment market are Ocugen, Kubota Vision Inc, Nanoscope Therapeutics Inc., RBP4 Pty Ltd, Stargazer Pharmaceuticals, Inc., Belite Bio, Inc, Alkeus Pharmaceuticals, Inc., IVERIC bio, Inc., Kubota Vision Inc., Astellas Institute, Nanoscope Therapeutics, Alkeus Pharmaceuticals, and others.
Stargardt Disease Market Summary
In 2023, the United States led the Stargardt Disease treatment market, accounting for nearly 55% of the global share, followed by the EU4, the UK, and Japan. Stargardt…
Helicobacter Pylori Infections Market Outlook 2034 - Clinical Trials, Market Siz …
Helicobacter Pylori Infections companies working in the market are Servatus Biopharmaceuticals, Cinclus Pharma Holding AB, Crestone, EpiVax, Iguana Biotechnology, ImevaX GmbH, ImmunoBiology, Luoxin Pharmaceuticals, Nexbiome Therapeutics, Recce Pharmaceuticals, RedHill Biopharma Ltd, SCG Cell Therapy Pte Ltd, Shanghai High-Tech Bioengineering Co Ltd, Takeda Pharmaceutical, TenNor Therapeutics, Trio Medicines, Xiamen Encheng Pharmaceutical Co Ltd and others.
Helicobacter Pylori Infections Market Summary
In 2022, the U.S. held the largest share of the Helicobacter pylori (H.…
Hereditary Angioedema Market Outlook 2034 - Clinical Trials, Market Size, Medica …
Hereditary Angioedema Companies are Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Astria Therapeutics, Pharvaris Netherlands B.V, Intellia Therapeutics, Takeda, CSL Behring, Shire, and others
Hereditary Angioedema Market Summary
The global Hereditary Angioedema (HAE) market was valued at around USD 3 billion in 2023 and is projected to grow significantly with the approval of new therapies. HAE is a rare genetic disorder marked by recurrent, severe…
More Releases for Graves
Graves' Disease Market New Product Development & Latest Trends
Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overproduction of thyroid hormones, through antibodies that stimulate the thyroid gland. It is among the most common thyroid-related autoimmune conditions, disproportionately affecting women between 30-60 years of age. Beyond metabolic complications such as weight loss, heat intolerance, and palpitations, Graves' disease can cause thyroid eye disease (TED), which impairs vision and quality of life.
For decades, treatment has relied on antithyroid…
Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Graves Ophthalmopathy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Graves Ophthalmopathy Research. Learn more about…
Search for graves and burials in Minsk
If you are looking for information about the location of the grave in Minsk or other regions of Belarus, the company https://verimby.com +375293887408 (Viber); +375447498518 (WhatsApp) offers professional assistance in this important matter. We specialize in finding burial sites, providing detailed data and providing support in restoring lost ties with the past, creating a family tree, even if you are in another country.
Why can the search for graves in Belarus…
Graves' Disease Treatment Market Size, Drugs, Companies 2034 | DelveInsight
Graves' Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves' Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Graves' Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves' Disease, historical and…
Japan Graves' disease Market Size & Growth Analysis Report, 2019-2025
Japan Graves' disease market is growing at a CAGR of around 4.7% during the forecast period. According to the WHO, around 10.1% of the country's population is suffering from diabetes, among which, the individuals suffering from type-1 diabetes are more prone to develop Grave's disease in the near future. According to IDF, around 2.2 per thousand children and adolescents aged 14 years and below are suffering from type-1 diabetes in…
Global Graves Disease Market Status and Outlook (2020-2025)
Global Info Research offers a latest published report on Graves Disease Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Graves Disease Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/515950/graves-disease
Market…
